Pictet Asset Management Ltd. increased its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 9.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 729,876 shares of the biopharmaceutical company’s stock after buying an additional 64,100 shares during the period. Pictet Asset Management Ltd. owned 0.69% of Lexicon Pharmaceuticals worth $2,197,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of LXRX. Commonwealth Equity Services LLC increased its position in Lexicon Pharmaceuticals by 40.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 4,746 shares in the last quarter. Trexquant Investment LP acquired a new position in Lexicon Pharmaceuticals in the 2nd quarter valued at approximately $92,000. Voloridge Investment Management LLC acquired a new position in Lexicon Pharmaceuticals in the 2nd quarter valued at approximately $105,000. Quantitative Systematic Strategies LLC increased its position in Lexicon Pharmaceuticals by 67.2% in the 2nd quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 8,302 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in Lexicon Pharmaceuticals in the 3rd quarter valued at approximately $202,000. 96.24% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have issued reports on the stock. BidaskClub cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Gabelli lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. They noted that the move was a valuation call. ValuEngine raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 16th. Finally, G.Research lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the stock. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $6.45.
LXRX traded up $0.15 during trading on Friday, hitting $4.26. 1,188,057 shares of the company’s stock were exchanged, compared to its average volume of 1,918,290. The company has a quick ratio of 8.01, a current ratio of 8.11 and a debt-to-equity ratio of 1.42. The business’s 50 day moving average is $4.07 and its two-hundred day moving average is $3.74. Lexicon Pharmaceuticals, Inc. has a fifty-two week low of $1.13 and a fifty-two week high of $8.39. The stock has a market cap of $436.78 million, a P/E ratio of 3.02 and a beta of 1.00.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.31 by $0.80. The company had revenue of $294.45 million during the quarter, compared to the consensus estimate of $12.00 million. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The firm’s revenue for the quarter was up 4124.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.26) earnings per share. On average, sell-side analysts forecast that Lexicon Pharmaceuticals, Inc. will post 1.01 earnings per share for the current year.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: Why do companies issue monthly dividends?
Receive News & Ratings for Lexicon Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.